Abstract:We assessed the effectiveness of nanopore long‐read sequencing for evaluatingmethylation levels across the MGMT CpG‐island, crucial for prognosis in glioblastomapatients. Using 165 CNS tumour samples, nanopore sequencing was compared toestablished techniques, showing a strong correlation with pyrosequencing and effectivepatient stratification via hierarchical clustering. Nanopore sequencing provided rapid,high‐confidence results and expanded analysis to all 98 CpGs of the MGMT CpG‐island,suggesting its utility for clinically relevant patient subgroup identification and warranting further exploration in clinical settings. Aims The methylation status of the O6‐methylguanine‐DNA methyltransferase (MGMT) promoter region is essential in evaluating the prognosis and predicting the drug response in patients with glioblastoma. In this study, we evaluated the utility of using nanopore long‐read sequencing as a method for assessing methylation levels throughout the MGMT CpG‐island, compared its performance to established techniques and demonstrated its clinical applicability. Methods We analysed 165 samples from CNS tumours, focusing on the MGMT CpG‐island using nanopore sequencing. Oxford Nanopore Technologies (ONT) MinION and PromethION flow cells were employed for single sample or barcoded assays, guided by a CRISPR/Cas9 protocol, adaptive sampling or as part of a whole genome sequencing assay. Methylation data obtained through nanopore sequencing were compared to results obtained via pyrosequencing and methylation bead arrays. Hierarchical clustering was applied to nanopore sequencing data for patient stratification. Results Nanopore sequencing displayed a strong correlation (R2 = 0.91) with pyrosequencing results for the four CpGs of MGMT analysed by both methods. The MGMT‐STP27 algorithm's classification was effectively reproduced using nanopore data. Unsupervised hierarchical clustering revealed distinct patterns in methylated and unmethylated samples, providing comparable survival prediction capabilities. Nanopore sequencing yielded high‐confidence results in a rapid timeframe, typically within hours of sequencing, and extended the analysis to all 98 CpGs of the MGMT CpG‐island. Conclusions This study presents nanopore sequencing as a valid and efficient method for determining MGMT promotor methylation status. It offers a comprehensive view of the MGMT promoter methylation landscape, which enables the identification of potentially clinically relevant subgroups of patients. Further exploration of the clinical implications of patient stratification using nanopore sequencing of MGMT is warranted.

PATH-01. ACCURATE AND RAPID PAEDIATRIC BRAIN TUMOR CLASSIFICATION (PBT) BY METHYLATION PROFILING USING NOVEL NATIVE REAL TIME OXFORD NANOPORE TECHNOLOGY SEQUENCING TECHNOLOGY

Towards accesible brain-tumor classification at the point of care: Nanopore methylation sequencing from Formalin-Fixed Paraffin-Embedded (FFPE) pathology samples

P1.01-18 Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases

PATH-05. RAPID SIMULTANEOUS IDH MUTATION AND MGMT METHYLATION STATUS ASSESSMENT IN GLIOMA PATIENTS USING CRISPR-Cas9-TARGETED NANOPORE SEQUENCING

ROBIN: A unified nanopore-based sequencing assay integrating real-time, intraoperative methylome classification and next-day comprehensive molecular brain tumour profiling for ultra-rapid tumour diagnostics

EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM

Transcriptome profiling of pediatric extracranial solid tumors and lymphomas enables rapid low-cost diagnostic classification

A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma

Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy

Cnsc-58. Bioprocessing Of Viable Surgical Pediatric Brain Tumor Specimens For Genome-Guided Personalized Drug Testing

BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES

Machine-learning operations streamlined clinical workflows of DNA methylation-based CNS tumor classification.

Accurate and comprehensive evaluation of O6‐methylguanine‐DNA methyltransferase promoter methylation by nanopore sequencing

DNA methylation‐array interlaboratory comparison trial demonstrates highly reproducible paediatric CNS tumour classification across 13 international centres

Rapid Intraoperative Amplicon Sequencing of CNS Tumor Markers

Rapid DNA methylation-based classification of pediatric brain tumors from ultrasonic aspirate specimens

Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groups

Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials

Validation of a 90-Gene Assay for Tissue Origin Diagnosis of Brain Metastases.

Diagnosis of pediatric central nervous system tumors using methylation profiling of cfDNA from cerebrospinal fluid

Unclassifiable CNS tumors in DNA methylation-based classification: clinical challenges and prognostic impact